Abeles I, Palma C, Meednu N, Payne AS, Looney RJ, Anolik JH. B cell-directed therapy in autoimmunity. Annu Rev Immunol. 2023. https://doi.org/10.1146/annurev-immunol-083122-044829.

Article  Google Scholar 

Hofmann K, Clauder AK, Manz RA. Targeting B cells and plasma cells in autoimmune diseases. Front Immunol. 2018;9:835. https://doi.org/10.3389/fimmu.2018.00835.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rawlings DJ, Metzler G, Wray-Dutra M, Jackson SW. Altered B cell signalling in autoimmunity. Nat Rev Immunol. 2017;17:421–36. https://doi.org/10.1038/nri.2017.24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Szili D, Cserhalmi M, Banko Z, Nagy G, Szymkowski DE, Sarmay G. Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcgammaRIIb and CD19. MAbs. 2014;6:991–9. https://doi.org/10.4161/mabs.28841.

Article  PubMed  PubMed Central  Google Scholar 

Perugino CA, Wallace ZS, Zack DJ, Quinn SM, Poma A, Fernandes AD, et al. Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial. Lancet Rheumatol. 2023;5:e442–50. https://doi.org/10.1016/S2665-9913(23)00157-1.

Article  CAS  PubMed  Google Scholar 

Merrill JT, Guthridge J, Smith M, June J, Koumpouras F, Machua W, et al. Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial. Arthritis Rheumatol. 2023;75:2185–94. https://doi.org/10.1002/art.42652.

Article  CAS  PubMed  Google Scholar 

Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, et al. Antibody-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011;186:4223–33. https://doi.org/10.4049/jimmunol.1003412.

Article  CAS  PubMed  Google Scholar 

Berentsen S, Fattizzo B, Barcellini W. The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket? Front Immunol. 2023;14:1180509. https://doi.org/10.3389/fimmu.2023.1180509.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sellebjerg F, Weber MS. Targeting B cells in multiple sclerosis. Curr Opin Neurol. 2021;34:295–302. https://doi.org/10.1097/wco.0000000000000938.

Article  CAS  PubMed  Google Scholar 

Zack D, Jaraczewska Baumann M, Korkosz M, Suljok G, Sramek P, Rojkovich B, et al. Results of a Phase 1b/2a study of the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb®5871 in patients with rheumatoid arthritis (RA) [abstract]. Arthritis Rheumatol. 2015;67 (suppl 10).

Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32:425–40. https://doi.org/10.1007/s40259-018-0295-0.

Article  PubMed  PubMed Central  Google Scholar 

Jin JF, Zhu LL, Chen M, Xu HM, Wang HF, Feng XQ, et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence. 2015;9:923–42. https://doi.org/10.2147/PPA.S87271.

Article  PubMed  PubMed Central  Google Scholar 

Epstein RS. Payer perspectives on intravenous versus subcutaneous administration of drugs. Clinicoecon Outcomes Res. 2021;13:801–7. https://doi.org/10.2147/CEOR.S317687.

Article  PubMed  PubMed Central  Google Scholar 

Jarvi NL, Balu-Iyer SV. Immunogenicity challenges associated with subcutaneous delivery of therapeutic proteins. BioDrugs. 2021;35:125–46. https://doi.org/10.1007/s40259-020-00465-4.

Article  PubMed  PubMed Central  Google Scholar 

Datta-Mannan A, Estwick S, Zhou C, Choi H, Douglass NE, Witcher DR, et al. Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies. MAbs. 2020;12:1770028. https://doi.org/10.1080/19420862.2020.1770028.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mueller C, Adler M. Switching from an IV to an SC formulation—considerations for formulation development and formulation bridging. Chall Protein Prod De. 2018. https://doi.org/10.1007/978-3-319-90603-4_26.

Article  Google Scholar 

Turner MR, Balu-Iyer SV. Challenges and opportunities for the subcutaneous delivery of therapeutic proteins. J Pharm Sci. 2018;107:1247–60. https://doi.org/10.1016/j.xphs.2018.01.007.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bittner B, Schmidt J. Clinical development of subcutaneous dosing alternatives to established intravenous formulations for monoclonal antibodies—pharmacokinetic-based bridging approach. In: Bittner B, Schmidt J, editors. Formulation and device lifecycle management of biotherapeutics. Academic Press; 2022. p. 47–83.

Chapter  Google Scholar 

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology. 2018;90:e1805–14. https://doi.org/10.1212/WNL.0000000000005516.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69:1016–27. https://doi.org/10.1002/art.40049.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davies A, Berge C, Boehnke A, Dadabhoy A, Lugtenburg P, Rule S, et al. Subcutaneous rituximab for the treatment of b-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017;34:2210–31. https://doi.org/10.1007/s12325-017-0610-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harvey MJ, Zhong Y, Morris E, Beverage JN, Epstein RS, Chawla AJ. Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma. PLoS ONE. 2022;17: e0261336. https://doi.org/10.1371/journal.pone.0261336.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Datta-Mannan A, Estwick, S, Zhou C, Choi H, Douglass NE, Witcher DR, et al. Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies. mAbs. 2020;12(1):1770028. https://doi.org/10.1080/19420862.2020.1770028.

Wang C, Zheng Q, Zhang M, Lu H. Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations. Br J Clin Pharmacol. 2019;85:114–25. https://doi.org/10.1111/bcp.13767.

Article  CAS  PubMed  Google Scholar 

Morrison M, Palermo G, Schmitt C. Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2015;71:1365–74. https://doi.org/10.1007/s00228-015-1938-4.

Article  CAS  PubMed  Google Scholar